Matching articles for "Didronel"
Issue 1367 · June 27, 2011 Free
Correction: In Brief: Delayed-Release Risedronate (Atelvia)

The In-Brief article on delayed-release risedronate in issue 1360 (Med Lett Drugs Ther 2011; 53:24) included a statement that alendronate is currently the only bisphosphonate available generically. That would…

Med Lett Drugs Ther. 2011 Jun 27; 53(1367):52
The In-Brief article on delayed-release risedronate in issue 1360 (Med Lett Drugs Ther 2011; 53:24) included a statement that alendronate is currently the only bisphosphonate available generically. That would have been accurate if we had added "that is FDA-approved for treatment of osteoporosis." Etidronate ( Didronel , and others), which was the first bisphosphonate used to treat osteoporosis (Medical Letter 1990; 32:111) but was never approved for such use by the FDA, is also available generically. It is approved for treatment of Paget's disease and for prevention and treatment of heterotropic ossification following hip replacement and in spinal-cord injured patients. Download U.S. English
Issue 38 · October 1, 2005
Drugs for Prevention and Treatment of Postmenopausal Osteoporosis

Many drugs are now marketed for treatment of postmenopausal osteoporosis, but questions remain about their use.

Treat Guidel Med Lett. 2005 Oct; 3(38):69-74
Many drugs are now marketed for treatment of postmenopausal osteoporosis, but questions remain about their use.
Issue 1207 · April 25, 2005
Alendronate and Risedronate

A 10-year study of daily oral alendronate (Fosamax) and a 7-year study of daily oral risedronate (Actonel) indicate that both drugs maintained increases in bone mineral density (BMD) and decreases in markers…

Med Lett Drugs Ther. 2005 Apr 25; 47(1207):33-5
A 10-year study of daily oral alendronate (Fosamax) and a 7-year study of daily oral risedronate (Actonel) indicate that both drugs maintained increases in bone mineral density (BMD) and decreases in markers of bone remodeling throughout the study period. Both drugs are now more commonly taken once weekly. Available data are insufficient to compare fracture rates with alendronate and risedronate, and fracture rates are considered the most important endpoint in osteoporosis studies. Recent reports of severe pain and jaw osteonecrosis with these drugs are disturbing.
Issue 3 · November 1, 2002
Drugs for Prevention and Treatment of Postmenopausal Osteoporosis

Many drugs are now marketed for treatment of post-menopausal osteoporosis (PD Delmas, Lancet 2002; 359:2018). Prevention of this disorder has been complicated by the news that hormone replacement therapy…

Treat Guidel Med Lett. 2002 Nov; 0(3):13-8
Many drugs are now marketed for treatment of post-menopausal osteoporosis (PD Delmas, Lancet 2002; 359:2018). Prevention of this disorder has been complicated by the news that hormone replacement therapy (HRT), which many women have been taking to prevent osteoporosis, increases the incidence of coronary heart disease and that of breast cancer, stroke and pulmonary embolism as well (Medical Letter 2002; 44:78).
Issue 1093 · November 27, 2000
Drugs that may cause Cognitive Disorders in the Elderly

Older patients are especially susceptible to drug-induced cognitive impairment. They are more likely to be taking multiple drugs, to have higher blood levels of those drugs because of renal or hepatic…

Med Lett Drugs Ther. 2000 Nov 27; 42(1093):111-2
Older patients are especially susceptible to drug-induced cognitive impairment. They are more likely to be taking multiple drugs, to have higher blood levels of those drugs because of renal or hepatic dysfunction, and to have pre-existing cognitive problems that make it difficult to detect the role of drugs causing new symptoms or making old ones worse.
Issue 1034 · August 28, 1998
Risedronate for Paget's Disease of Bone

Risedronate ( Actonel - Procter & Gamble), a pyridinyl bisphosphonate, has been approved by the FDA for oral treatment of Paget's disease of bone. Characterized by excessive bone resorption, bony deformity,…

Med Lett Drugs Ther. 1998 Aug 28; 40(1034):87-8
Risedronate ( Actonel - Procter & Gamble), a pyridinyl bisphosphonate, has been approved by the FDA for oral treatment of Paget's disease of bone. Characterized by excessive bone resorption, bony deformity, disorganized bone remodeling and structural weakness, Paget's disease occurs in up to 3% of people older than 55 in Europe and North America (PD Delmas and PJ Meunier, N Engl J Med, 336:558, 1997).
Issue 1005 · July 18, 1997
Tiludronate for Paget's Disease of Bone

Tiludronate ( Skelid - Sanofi), a chloro-4-phenylthiomethylene bisphosphonate, has been approved by the US Food and Drug Administration (FDA) for treatment of Paget's disease of bone. Characterized by…

Med Lett Drugs Ther. 1997 Jul 18; 39(1005):65-6
Tiludronate ( Skelid - Sanofi), a chloro-4-phenylthiomethylene bisphosphonate, has been approved by the US Food and Drug Administration (FDA) for treatment of Paget's disease of bone. Characterized by excessive bone resorption and disorganized bone remodeling, Paget's disease occurs in up to 3% of people more than 55 years old in Europe and North America (PD Delmas and PJ Meunier, N Engl J Med, 336:558, Feb 20, 1997).
Issue 965 · January 5, 1996
New Drugs for Osteoporosis

Two new drugs alendronate ( Fosamax - Merck) and salmon calcitonin nasalspray ( Miacalcin - Sandoz) are now available in the USA for treatment of postmenopausalosteoporosis. A third drug for treatment of…

Med Lett Drugs Ther. 1996 Jan 5; 38(965):1-3
Two new drugs alendronate ( Fosamax - Merck) and salmon calcitonin nasalspray ( Miacalcin - Sandoz) are now available in the USA for treatment of postmenopausalosteoporosis. A third drug for treatment of osteoporosis, a slow-release fluoridepreparation ( Slow Fluoride -Mission Pharmacal), has been recommended for approvalby an advisory committee of the US Food and Drug Administration (FDA). Various formulationsof fluoride have been available in Europe for this indication for many years.
Issue 882 · October 30, 1992
Choice of Drugs for Postmenopausal Osteoporosis

The bone mass of an average person reaches a maximum at the age of 25 to 30, stays the same for about 15 years, and then progressively declines at a rate of 0.2% to 0.5% per year. At menopause, women go…

Med Lett Drugs Ther. 1992 Oct 30; 34(882):101-2
The bone mass of an average person reaches a maximum at the age of 25 to 30, stays the same for about 15 years, and then progressively declines at a rate of 0.2% to 0.5% per year. At menopause, women go through a period of increased bone resorption (2% per year) for about 10 years and then resume a gradual rate of bone loss. Current strategies for prevention and treatment of Postmenopausal Osteoporosis include increasing calcium intake to maximize peak bone mass, using antiresorptive drugs to decrease postmenopausal resorption, and using other drugs to stimulate bone systhesis (BL Riggs and LJ Melton, III, N Engl J Med, 327:620, Aug 27, 1992).
Issue 861 · January 10, 1992
Pamidronate

Disodium pamidronate ( Aredia - Ciba-Geigy), an aminohydroxypropilidene bisphosphonate, has been approved by the US Food and Drug Administration for intravenous (IV) treatment of hypercalcemia associated with…

Med Lett Drugs Ther. 1992 Jan 10; 34(861):1-2
Disodium pamidronate ( Aredia - Ciba-Geigy), an aminohydroxypropilidene bisphosphonate, has been approved by the US Food and Drug Administration for intravenous (IV) treatment of hypercalcemia associated with malignancy, with or without bone metastases. The drug is also being investigated for use in Paget's disease of bone, hyperparathyroidism, and postmenopausal osteoporosis. An oral formulation of pamidronate has been used in Europe, but is not available in the USA.
Issue 833 · December 14, 1990
Etidronate for Postmenopausal Osteoporosis

Etidronate (e ti droe' nate) disodium ( Didronel - Norwich Eaton), an oral bisphosphonate available for many years for treatment of Paget's disease (Medical Letter, 20:78, 1978), recently has also been used…

Med Lett Drugs Ther. 1990 Dec 14; 32(833):111-4
Etidronate (e ti droe' nate) disodium ( Didronel - Norwich Eaton), an oral bisphosphonate available for many years for treatment of Paget's disease (Medical Letter, 20:78, 1978), recently has also been used for treatment of postmenopausal osteoporosis.